12:00 AM
 | 
Jun 04, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Prezista darunavir regulatory update

FDA issued a complete response letter for an sNDA from Johnson & Johnson's Janssen Therapeutics division for a single 800...

Read the full 79 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >